Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis

• Status: Completed
• Trial end date: 2021-05-03
• Target enrollment: 0
• Participant gender: All

Summary

This Phase 2 study will assess efficacy, safety, and tolerability of TER-101 ointment and vehicle twice daily for 28 days in adult and adolescent subjects with mild to moderate atopic dermatitis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Teres Bio, Inc.

Criteria

Inclusion Criteria:

• Adolescent or adult subject aged 12 - 65 years.

• Overall IGA score of 2 (mild) or 3 (moderate) at baseline on a 5-point IGA

Exclusion Criteria:

• AD with known hypersensitivity to excipients of TER-101 Ointment

• Subjects who are immunocompromised